DK2059234T3 - Fremgangsmåde til at lindre inflammation i fordøjelseskanalen - Google Patents

Fremgangsmåde til at lindre inflammation i fordøjelseskanalen

Info

Publication number
DK2059234T3
DK2059234T3 DK07814746.9T DK07814746T DK2059234T3 DK 2059234 T3 DK2059234 T3 DK 2059234T3 DK 07814746 T DK07814746 T DK 07814746T DK 2059234 T3 DK2059234 T3 DK 2059234T3
Authority
DK
Denmark
Prior art keywords
digestive tract
relieving inflammation
subject
inflammation
reducing
Prior art date
Application number
DK07814746.9T
Other languages
English (en)
Inventor
Louis Anthony Tartaglia
Thomas Michael Barnes
Robert Mark Coopersmith
Scott Edward Malstrom
David William White
Dominic Picarella
Original Assignee
Ore Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ore Pharmaceuticals Inc filed Critical Ore Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2059234T3 publication Critical patent/DK2059234T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
DK07814746.9T 2006-09-08 2007-09-07 Fremgangsmåde til at lindre inflammation i fordøjelseskanalen DK2059234T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82507506P 2006-09-08 2006-09-08
US82780706P 2006-10-02 2006-10-02
PCT/US2007/077857 WO2008031014A1 (en) 2006-09-08 2007-09-07 Method for reducing or alleviating inflammation in the digestive tract

Publications (1)

Publication Number Publication Date
DK2059234T3 true DK2059234T3 (da) 2011-11-28

Family

ID=38670723

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07814746.9T DK2059234T3 (da) 2006-09-08 2007-09-07 Fremgangsmåde til at lindre inflammation i fordøjelseskanalen

Country Status (11)

Country Link
US (1) US20080234345A1 (da)
EP (1) EP2059234B1 (da)
JP (1) JP2010502736A (da)
CN (1) CN101568331A (da)
AT (1) ATE531362T1 (da)
AU (1) AU2007292247A1 (da)
CA (1) CA2662535A1 (da)
DK (1) DK2059234T3 (da)
ES (1) ES2376493T3 (da)
IL (1) IL197362A0 (da)
WO (1) WO2008031014A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
WO2009114516A1 (en) * 2008-03-10 2009-09-17 Ore Pharmaceuticals Inc. Therapy for disorders of the proximal digestive tract
WO2010093804A1 (en) * 2009-02-12 2010-08-19 Ore Pharmaceuticals, Inc. Ace2 inhibitors for reducing gastrointestinal adverse effects of cytotoxic agents
WO2011108638A1 (ja) * 2010-03-04 2011-09-09 大日本住友製薬株式会社 炎症性腸疾患用薬剤
KR101713453B1 (ko) 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
KR20170139074A (ko) 2015-04-24 2017-12-18 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
GB202116266D0 (en) * 2021-11-11 2021-12-29 Bicycletx Ltd Novel use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US6632830B1 (en) * 1999-04-30 2003-10-14 Millennium Pharmaceuticals, Inc. ACE-2 inhibiting compounds and methods of use thereof
US7045532B2 (en) 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
US6900033B2 (en) * 2001-06-04 2005-05-31 Human Genome Sciences, Inc. Methods and compositions for modulating ACE-2 activity
GB0203061D0 (en) 2002-02-08 2002-03-27 Novartis Ag Organic compounds
AU2003299196A1 (en) * 2002-09-24 2004-04-23 Combinatorx, Incorporated Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
TW200509958A (en) * 2003-02-14 2005-03-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050203168A1 (en) * 2004-03-11 2005-09-15 The Regents Of The University Of Michigan Angiotensin converting enzyme inhibitor use for treatment and prevention of gastrointestinal disorders
WO2008031013A1 (en) * 2006-09-08 2008-03-13 Gene Logic Inc. Method for treating inflammatory diseases of the digestive tract

Also Published As

Publication number Publication date
IL197362A0 (en) 2009-12-24
ES2376493T3 (es) 2012-03-14
CN101568331A (zh) 2009-10-28
CA2662535A1 (en) 2008-03-13
AU2007292247A1 (en) 2008-03-13
EP2059234A1 (en) 2009-05-20
ATE531362T1 (de) 2011-11-15
EP2059234B1 (en) 2011-11-02
AU2007292247A2 (en) 2009-03-26
WO2008031014A1 (en) 2008-03-13
JP2010502736A (ja) 2010-01-28
US20080234345A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
DK2059234T3 (da) Fremgangsmåde til at lindre inflammation i fordøjelseskanalen
MX2009011749A (es) Compuestos triciclicos como inhibidores de metaloproteinasa matricial.
WO2008016887A3 (en) Methods and pharmaceutical compositions to treat gastric acid disorders
EA201500769A1 (ru) Ингибиторы е1 активирующих ферментов
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
MX2010004454A (es) Anti-proproteina convertasa subtilisina/kexina tipo 9 y metodos para tratar trastornos de lipidos y colesterol.
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
NZ594365A (en) Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders
EA201001496A1 (ru) Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии
MX337634B (es) Anillos intravaginales monoliticos que comprenden progesterona y metodos de manufactura y uso de los mismos.
WO2009158432A3 (en) Ang-2 inhibition to treat multiple sclerosis
EA201101435A1 (ru) Имидазотиадиазолы для применения в качестве ингибиторов киназ
UY28860A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
HK1202628A1 (en) Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
WO2010062900A3 (en) A new family of pain producing substances and methods to produce novel analgesic drugs
GEP20125458B (en) Matrix metalloproteinase inhibitors
WO2008106166A3 (en) Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
MX2011004870A (es) Composicion de combinacion que comprende un inhibidor de dhodh y metotrexato para tratar enfermedades autoinmunes.
WO2006132959A3 (en) Inhibition of thrombin generation
UY31325A1 (es) Composiciones y métodos para tratar enfermedades y trastornos inmunologicos e inflamatorios
WO2007084651A3 (en) Methods and kits to treat chronic inflammatory immune diseases
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
WO2007084542A3 (en) Treatment of inflammatory disorders with triazole compounds
WO2009155070A3 (en) Compositions and methods for treatment of inflammation and hyperkeratotic lesions
WO2007097980A3 (en) Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy